1GI M,Zarebinski M,Adamusl:Plasma fibrinogen and troponin Ⅰ in acute coronary syndrome and stable angina[J].Int Cardiol,2002,83(1):43-46.
2Rider PM.High-Sensitivity C-reactive protein and cardiol vascularrisk:rationale for screening and primary prevention[J].Am J Cardiol,2003,92(suppl):17-22.
3Yokota T,Oritani K,Takahashi I,et al.Adiponectin,a new member of the family of soluble defense collagens,negatively regulates the growth of mylomonocytic,progenitors and the functions of macrophages[J].Blood,2000,96:1723-1732.
4Devaraj S,Xu DY,Jialal I.C-reactive protein increase plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells:implications for the metabolic syndrome and atherothrombosis[J].Circulation,2003,107:398-404.
5Hotta K,Funabashi T,Arita Y,et al.Plasma concentrations of a novel,adipose-specific protein,adiponectin,in type 2 diabetic patients[J].Arterioseler Thromb Vase Biol,2000,20:1595-1599.
6Matsuda M,Shimomura I,Sata M,et al.Role of adiponectin in preventing vascular stenosis the missing link of adipo-vascular axis[J].J Biol Chem,2002,277:37487-37491.
7Oachi N,Kihara S,Funabashi T,et al.Novel madulator for endothelial adhesion modecules:adipocyte-derived plasma protein adiponectin[J].Circulation,1999,100:2473-2476.
8Hulea SA, Wasowicz E, Kummerow FA. Inhibition of metalcatalyzed oxidation of low-density lipoprotein by free and albuminbound bilirubin [J]. Biochem Biophys Acta, 1995,1259(1):29-38.
9Torzewsk J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries [J] .Artierioscler Thromb Vasc Boil,1998,18(6):1386-1392.
10Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease [J] . Clin Chem, 2000 ,46(11):1723-1727.
4Eggers KM, Lagerqvist B, V enge PI Prognostic value of biomarkersduringand after non-ST-segment elevation acute coronary synd-rome[J].Am Coll Cardio, 2009, 54 ( 4 ): 357- 364.
5Rider PM. High- Sensitivity C-reactive protein and cardio lv ascularrisk: rationale fo r screening and primary prevention[J]. Am J Cardiol,2003, 92( suppl): 17- 22.
6Weber M,Bazzino 0,Navarro Estrada JL,et al. N-terminal B-typenatriuretic peptide assessment provides incrementalprognostic infor-mation in patients with acute coronary syndromes and normal tro-ponin T values upon admission[J]. J Am Coll Cardio, 2008,51( 12):1188-1195.
7De Lemos JA, Morrow DA, Blazing MA,et al. Serial measurement ofmonocyte chemoattractant protein-1 after acutecoronary syndromes:results from the A to Z trial[J]. Am J Cardiol ,2007,50( 27): 2117-2124.
8Mayer 0 Jr, Simon J, Plskov M. N-terminal pro B- type natriu retiepeptide as prognostic marker for mortality in coron ary patients without clinically manifest heart failure[j]. Eur Epidemio, 2009, 24 (7):363-368.
9Ladue JS,Wroblewski F,Karmen A.Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction. Science . 1954
10Okamoto F,Sohmiya K,Ohkaru Y,et al.Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction.Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clinical Chemistry . 2000